To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03682276
Title Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (PRIME-HCC)
Acronym PRIME-HCC
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Imperial College London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Facility Status City State Zip Country Details
Imperial College Healthcare NHS Trust RECRUITING London Greater London W12 0HS United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field